7 results on '"Norata, Giuseppe D."'
Search Results
2. Contributors
- Author
-
Balasubramanyam, Ashok, primary, Ballantyne, Christie M., additional, Barter, Philip J., additional, Blumenthal, Roger S., additional, Boffa, Michael B., additional, Brewer, Bryan, additional, Brinton, Eliot A., additional, Brothers, Julie A., additional, Carlson, Lars A., additional, Catapano, Alberico L., additional, Chiavaroli, Laura, additional, Church, Timothy S., additional, Cohen, David E., additional, Creider, Julia C., additional, Daniels, Stephen R., additional, Davidson, David J., additional, Davidson, Michael H., additional, Deedwania, Prakash, additional, deGoma, Emil M., additional, Do, Rose Q., additional, Fayad, Zahi A., additional, Fazio, Sergio, additional, Fellstrøm, Bengt, additional, Fleming, Jennifer, additional, Gillard, Baiba K., additional, Ginsberg, Henry N., additional, Goldberg, Anne Carol, additional, Gotto, Antonio M., additional, Guyton, John R., additional, Harris, William S., additional, Hegele, Robert A., additional, Holdaas, Hallvard, additional, Hoogeveen, Ron C., additional, Jacobson, Terry A., additional, Jardine, Alan G., additional, Jenkins, David J.A., additional, Johnson, Amber E., additional, Jones, Peter, additional, Jones, Peter H., additional, Kastelein, John J.P., additional, Kendall, Cyril W.C., additional, Kobashigawa, Jon, additional, Koschinsky, Marlys L., additional, Kris-Etherton, Penny M., additional, Kuivenhoven, Jan Albert, additional, Lairez, Olivier, additional, Lavie, Carl J., additional, Libby, Peter, additional, Linton, MacRae F., additional, Marcovina, Santica M., additional, Mark, Patrick B., additional, Martin, Seth S., additional, McGovern, Mark E., additional, McKenney, James M., additional, Miller, Michael, additional, Miller, Yury I., additional, Mirrahimi, Arash, additional, Moon, Jennifer E., additional, Moriarty, Patrick M., additional, Motazacker, Mohammad Mahdi, additional, Nambi, Vijay, additional, Negi, Smita I., additional, Nicholls, Stephen J., additional, Nissen, Steven E., additional, Norata, Giuseppe D., additional, Patel, Payal S., additional, Patel, Rajan K., additional, Xavier Pi-Sunyer, F., additional, Pokharel, Yashashwi, additional, Pownall, Henry J., additional, Raal, Frederick, additional, Rader, Daniel J., additional, Reyes-Soffer, Gissette, additional, Ridker, Paul M., additional, Rosales, Corina, additional, Rosenson, Robert S., additional, Roth, Eli M., additional, Rye, Kerry-Anne, additional, Santos, Raul D., additional, Sarzynski, Mark A., additional, Schwartz, Gregory G., additional, Sekhar, Rajagopal V., additional, Singh, Parmanand, additional, Skulas-Ray, Ann C., additional, Srichaikul, Kristie, additional, Stafforini, Diana M., additional, Stein, Evan A., additional, Stone, Neil J., additional, Swift, Damon L., additional, Tawakol, Ahmed, additional, Taylor, Allen J., additional, Tsimikas, Sotirios, additional, Turner, Traci, additional, Vijayaraghavan, Krishnaswami, additional, Virani, Salim S., additional, Wang, David Q.-H., additional, Wenger, Nanette K., additional, Wilkinson, Michael J., additional, and Wong, Julia M.W., additional
- Published
- 2015
- Full Text
- View/download PDF
3. Gonadal sex vs genetic sex in experimental atherosclerosis.
- Author
-
Nour J, Bonacina F, and Norata GD
- Subjects
- Humans, Male, Female, Menopause physiology, Hormone Replacement Therapy, Inflammation metabolism, Sex Characteristics, Gonadal Steroid Hormones metabolism, Atherosclerosis genetics
- Abstract
Epidemiological data and interventional studies with hormone replacement therapy suggest that women, at least until menopause, are at decreased cardiovascular risk compared to men. Still the molecular mechanisms beyond this difference are debated and the investigation in experimental models of atherosclerosis has been pivotal to prove that the activation of the estrogen receptor is atheroprotective, despite not enough to explain the differences reported in cardiovascular disease between male and female. This casts also for investigating the importance of the sex chromosome complement (genetic sex) beyond the contribution of sex hormones (gonadal sex) on atherosclerosis. Aim of this review is to present the dualism between gonadal sex and genetic sex with a focus on the data available from experimental models. The molecular mechanisms driving changes in lipid metabolism, immuno-inflammatory reactivity and vascular response in males and females that affect atherosclerosis progression will be discussed., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
4. Cholesterol metabolism, pancreatic β-cell function and diabetes.
- Author
-
Perego C, Da Dalt L, Pirillo A, Galli A, Catapano AL, and Norata GD
- Subjects
- ATP Binding Cassette Transporter 1 genetics, ATP Binding Cassette Transporter 1 metabolism, Cardiovascular Diseases drug therapy, Cholesterol, LDL blood, Diabetes Mellitus, Type 2 etiology, Diabetes Mellitus, Type 2 metabolism, Diabetes Mellitus, Type 2 pathology, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Proprotein Convertase 9 genetics, Receptors, LDL genetics, Receptors, LDL metabolism, Cholesterol metabolism, Insulin-Secreting Cells metabolism
- Abstract
Cholesterol plays an essential role in determining cell membrane physico-chemical characteristics and functions. A proper membrane structure is critical in pancreatic β-cells for glucose-mediated insulin secretion, and alterations in cellular cholesterol content may negatively affect this process, leading to β-cell dysfunction. The low density lipoprotein receptor (LDL-R) appears to play a relevant role in ß-cell dysfunction due to cholesterol accumulation. This observation raised the question of whether hypocholesterolemic drugs which increase LDL-R expression might bear diabetogenic properties, thus increasing the risk of new-onset diabetes or worsen glycaemic parameters in diabetic patients. Being at higher cardiovascular risk, diabetic patients are usually treated with hypolipidemic drugs to correct the atherogenic dyslipidemia characteristic of this pathological condition. Statin therapy has been associated with an increased incidence of new-onset diabetes (NOD), being the diabetogenic effect depending on the type and dose of statin. However, it is worth noting that the benefits on cardiovascular mortality largely exceed the increased risk associated with the development of diabetes. Although genetic variants associated with lower levels of LDL-C are also associated with an increased NOD risk, clinical trials with lipid-lowering drugs other than statins, namely ezetimibe or monoclonal antibodies against PCSK9, did not observe an increase of developing diabetes. In summary, molecular evidence clearly points to a key role for cholesterol homeostasis in pancreatic β-cell function which, in humans, is negatively affected by statins. Available data exclude that this could be the case for other hypocholesterolemic approaches, but long-term studies are warranted to explore this critical aspect., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
5. Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment.
- Author
-
Garetto S, Trovato AE, Lleo A, Sala F, Martini E, Betz AG, Norata GD, Invernizzi P, and Kallikourdis M
- Subjects
- Animals, Cell Proliferation, Diet, Atherogenic adverse effects, Disease Models, Animal, Disease Progression, Female, Humans, Mice, Mice, Inbred C57BL, Mice, Knockout, Receptors, LDL genetics, Arthritis immunology, Atherosclerosis immunology, Autoimmune Diseases immunology, Inflammation immunology, Liver Cirrhosis, Biliary immunology, T-Lymphocytes, Regulatory immunology
- Abstract
Regulatory T cells (Treg) influence the development of autoimmunity and their use is increasingly proposed for clinical applications. The well-characterized suppressive potential of Treg frequently leads to the assumption that Treg presence in prevailing numbers is indicative of immunosuppression. We hypothesized that this assumption may be false. We examined models of three different diseases caused by organ-specific autoimmune responses: primary biliary cirrhosis, atherosclerosis and rheumatoid arthritis (RA). We examined indicators of relative abundance of Treg compared to pro-inflammatory T cells, during peak inflammation. In all cases, the results were compatible with a relative enrichment of Treg at the site of inflammation or its most proximal draining lymph node. Conversely, in healthy mice or mice successfully protected from disease via a Treg-mediated mechanism, the data did not suggest that any Treg accumulation was occurring. This counter-intuitive finding may appear to be at odds with the immunosuppressive nature of Treg. Yet extensive previous studies in RA show that an accumulation of Treg occurs at peak inflammation, albeit without resulting in suppression, as the Treg suppressive function is overcome by the cytokine-rich environment. We suggest that this is a ubiquitous feature of autoimmune inflammation. Treg abundance in patient samples is increasingly used as an indicator of a state of immunosuppression. We conclude that this strategy should be revisited as it may potentially be a source of misinterpretation., (Copyright © 2015 The Authors. Published by Elsevier GmbH.. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
6. Homozygous familial hypobetalipoproteinemia: two novel mutations in the splicing sites of apolipoprotein B gene and review of the literature.
- Author
-
Cefalù AB, Norata GD, Ghiglioni DG, Noto D, Uboldi P, Garlaschelli K, Baragetti A, Spina R, Valenti V, Pederiva C, Riva E, Terracciano L, Zoja A, Grigore L, Averna MR, and Catapano AL
- Subjects
- Abetalipoproteinemia genetics, Adult, Alternative Splicing, Cholesterol blood, Cholesterol, LDL blood, DNA Mutational Analysis, Female, Humans, Infant, Introns, Male, Apolipoprotein B-100 genetics, Homozygote, Hypobetalipoproteinemias diagnosis, Hypobetalipoproteinemias genetics, Mutation
- Abstract
Objective: Familial hypobetalipoproteinemia (FHBL) is autosomal codominant disorder of lipoprotein metabolism characterized by low plasma levels of total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C) and apolipoprotein B (apoB) below the 5(th) percentile of the distribution in the population. Patients with the clinical diagnosis of homozygous FHBL (Ho-FHBL) are extremely rare and few patients have been characterized at the molecular level. Here we report the medical history and the molecular characterization of one paediatric patient with clinical features of Ho-FHBL., Methods: A one month old infant with failure to thrive, severe hypocholesterolemia and acanthocytosis was clinically and genetically characterized. Molecular characterization of the proband and her parents was performed by direct sequencing of the APOB gene and functional role of the identified mutations was assessed by the minigene methodology., Results: The proband was found carrying two novel splicing mutations of the APOB gene (c.3696+1G > C and c.3697-1G > A). CHOK1H8 cells expressing minigenes harbouring the mutations showed that these two mutations were associated with the retention of intron 23 and skipping of exon 24, resulting in two truncated apoB fragments of approximate size of 26-28 % of ApoB-100 and the total absence of apoB., Conclusion: We describe the first case of Ho-FHBL due to two splicing mutations affecting both the donor and the acceptor splice sites of the same intron of the APOB gene occurring in the same patient. The clinical management of the proband is discussed and a review of the clinical and genetic features of the published Ho-FHBL cases is reported., (Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
7. High-density lipoprotein subfraction 3 decreases ADAMTS-1 expression induced by lipopolysaccharide and tumor necrosis factor-alpha in human endothelial cells.
- Author
-
Norata GD, Björk H, Hamsten A, Catapano AL, and Eriksson P
- Subjects
- ADAM Proteins, ADAMTS1 Protein, Cells, Cultured, Disintegrins genetics, Gene Expression drug effects, Humans, Lipoproteins, HDL pharmacology, Lipoproteins, HDL3, Metalloendopeptidases genetics, Metalloproteases metabolism, RNA, Messenger metabolism, Disintegrins antagonists & inhibitors, Endothelial Cells metabolism, Lipopolysaccharides pharmacology, Lipoproteins, HDL physiology, Metalloendopeptidases antagonists & inhibitors, Tumor Necrosis Factor-alpha pharmacology
- Abstract
Endothelial expression of matrix metalloproteinases has been implicated in angiogenesis and endothelial cell proliferation. Recently, it has been shown that high-density lipoproteins (HDLs) promote angiogenesis. In the present study, we investigated the effects of native HDLs on the expression of several proteases and their inhibitors in human umbilical vein endothelial cells. We show that ADAMTS-1 (a disintegrin and metalloproteinase with thrombospondin motif) was potently induced by incubation with lipopolysaccharide or tumor necrosis factor-alpha and that the expression was significantly reduced in the presence of HDL subfraction 3. Since ADAMTS-1 has recently been shown to inhibit endothelial cell proliferation, the result of the present work may represent a new mechanism by which HDL could have a positive effect on endothelial cell and vascular wall function.
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.